- Oops!Something went wrong.Please try again later.
- Company routinely enjoys end-of-year bump in sales
- Early indications suggest solid demand for highly effective pain relief device
- Current cyber special offering $300 discount runs through December 23rd
- With $4.2 million in inventory, Electromedical setting stage for major sales ahead
SCOTTSDALE, Ariz., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that its annual product special offer is generating solid demand and interest, which is typical of this holiday season cyber campaign. The current cyber sale includes a $300 discount off of the flagship WellnessPro+ price and continues through December 23, 2020.
Electromedical Technologies has roughly $4.2 million of the product in inventory and management plans to sell most of its units during this campaign and through future sales events. These initiatives are ahead of the prospective launch of the WellnessPlus POD, which is currently under development. The WellnessPlus POD is positioned as a new, professional grade device for retail customers that is smaller, has more features, and is less expensive than existing commercial models.
Matthew Wolfson, Founder and CEO of EMED, commented, “Every year we launch our Cyber Monday promo, we enjoy a spike in sales. Demand and interest remain solid thus far this holiday season, aided by a meaningful $300 device discount. With over 10,000 products sold over the years, we are pleased to have helped our customers with relief from their chronic pain through electrotherapy and look forward to providing comfort and relief to many more ahead. We plan to engage in various campaigns to sell most of our remaining products as we develop our new WellnessPlus POD and prepare for its prospective launch late next year.”
About Electromedical Technologies
Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies
For more information, visit www.electromedtech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Electromedical Technologies, Inc.